Myocarditis and Decompensated Heart Failure
SARS-CoV2 has been implicated in cases of myocarditis and acute decompensated heart failure. Initial reports of myocarditis from China described cases of cardiogenic shock and reduced left ventricular ejection fraction among COVID-19 patients [
37,
38]. These patients had extremely elevated levels of cardiac biomarkers (namely troponin, CK-MB, and BNP) and required inotropy or extracorporeal membrane oxygenation (ECMO) to maintain adequate cardiac output. Based on the clinical presentation and on these elevations in biomarkers, these cases were deemed “fulminant myocarditis” and were treated with a combination of steroids, IVIG, antivirals, antibiotics, anti-inflammatory agents, renal replacement, and mechanical ventilation.
During other outbreaks of similar coronaviruses in the last 20 years, namely SARS-CoV and MERS, there was evidence to support direct myocardial involvement. Among patients who died from SARS-CoV in Toronto, Canada, viral RNA was detected in 35% of samples and the presence of viral RNA was associated with increased levels of interstitial fibrosis and macrophage activity within the myocardium, thus potentially leading to a more rapid clinical course compared to patients without viral RNA in the myocardium [
39]. However, hemodynamically significant myocarditis appears to have been a relatively rare complication of SARS, with one case series noting only one instance of potential myocarditis requiring inotropy among 121 cases [
40]. Myocarditis also appears to have been a potential complication during the MERS outbreak, with MRI findings consistent with myocarditis reported [
41].
There is now additional evidence that SARS-CoV2 has a similar effect on the myocardium as SARS-CoV and MERS. Myocardial involvement has been confirmed in SARS-CoV-2-positive patients via MRI and endomyocardial biopsy [
42‐
44]. Cardiac biopsy findings in COVID-19 patients have shown inflammatory infiltration of the myocardium with T-lymphocyte and macrophages, interstitial edema, and in some cases, evidence of cytoplasmic vacuoles indicating direct viral involvement of myocardial cells [
43,
44]. In a post-mortem case series of 68 patients from China, 7% of COVID-19 patients died of circulatory failure with some degree of myocardial involvement, as marked by elevations in troponin [
32]. However, it is unclear if these cases can truly be classified as myocarditis given the lack of ejection fraction assessment via TTE, MRI, or biopsy. From a different case series in Seattle, WA, troponin elevation was seen in 15% of patients, but none of the patients who underwent TTE had evidence of a reduced ejection fraction [
45]. There is currently no standardized approach to treatment of COVID-19 cardiomyopathy. In cases of more severe “fulminant” myocarditis resulting in cardiogenic shock, treatments with immunomodulating drugs, namely steroids and IVIG, but also more specific agents like tocilizumab to inhibit IL-6, are being used. Clinical trial data is as of yet lacking on the efficacy of such therapies in COVID-19-related myocarditis and are being extrapolated from other causes of fulminant myocarditis, namely giant cell subtype.
Decompensation of pre-existing heart failure appears to be a more common cardiovascular manifestation of SARS-CoV-2 infection than clinically significant myocarditis. Prior to the COVID-19 pandemic, influenza-like respiratory infections significantly increased the risk of hospitalization for decompensated heart failure, and in high influenza activity months, may contribute to 19% of heart failure hospitalizations across the United States [
46]. The relationship between respiratory infection and decompensated heart failure appears to also be true for COVID-19-like seasonal influenza. In two retrospective case series from China of 113 and 191 patients, heart failure was observed in 49% and 52% of deaths, respectively [
3,
47]. There appears to be a broad spectrum of disease severity, ranging from stable to fulminant heart failure requiring inotropes, and potentially mechanical circulatory support for refractory shock and or hypoxia. The use of ECMO in COVID-19 cases is being studied in a prospective manner as part of the Extracorporeal Life Support Organization (ELSO) Registry. As of June 1, 2020, ECMO has been used in 1135 COVID-19-confirmed cases worldwide, with 52% discharged alive, and the vast majority of patients receiving veno-venous ECMO for respiratory support [
48].
There is interest in the role of ACEI/ARB in both the overall risk of COVID-19 and the severity of lung disease with studies suggesting both the possibility of deleterious and beneficial effects [
49,
50]. Major guideline committees have continued to advocate for the use of ACE/ARB medications in hemodynamically stable heart failure patients, hypertension, and those with ischemic heart disease [
51,
52].
Acute Coronary Syndromes and Thrombosis
COVID-19 has been hypothesized to increase the risk of acute coronary syndromes (ACS) and systemic thrombosis. This premise is based on prior experience with viral infections such as influenza, which predisposes patients to developing ACS, and may increase the risk of myocardial infarction (MI) by at least sixfold in the week following infection [
53]. This increase in MI incidence is also seen following infection with other respiratory infections such as respiratory syncytial virus, and for non-viral respiratory illnesses such as bacterial pneumonia. Many MIs due to COVID-19 disease are likely related to supply–demand mismatch from hypoxia resulting in myocardial injury and troponin release. However, MI from acute atherothrombotic events were first reported in Wuhan, China, soon after the onset of the pandemic. As such, Chinese hospitals soon developed treatment algorithms aimed at providing urgent reperfusion to COVID-19-suspected patients while maintaining the safety of catheterization lab staff. In the setting of ST-elevation MI (STEMI) and suspected SARS-CoV-2 infection, thrombolytics were often the first choice for acute reperfusion therapy in China [
54]. Following this early experience in China, ACC/SCAI released a joint recommendation outlining care for COVID-19-suspected patients [
55]. This document highlights the need for adequate personal protective equipment for catheterization lab staff, the need to differentiate true ACS from supply–demand mismatch, consideration of deferring invasive angiography in low-risk non-ST elevation myocardial infarction (NSTEMI) patients until hospital resources improve, and the potential use of thrombolytics for ST segment elevation myocardial infarction (STEMI) cases where the risks of exposing staff to SARS-CoV2 outweigh the benefits of a primary percutaneous coronary intervention (PCI)-based approach. However, the authors still expect primary PCI to remain the standard of care for patients with STEMI and possible COVID-19 and thrombolytics reserved for non-PCI-capable hospitals [
56].
Further adding to the complexity of treating these patients, ST-segment elevations are seen in COVID-19 patients who are then found to have non-obstructive coronary disease. In a case series of 18 patients in New York, NY, who developed ST-segment elevations, nine patients underwent invasive angiography. Of these nine patients, three had no obstructive coronary artery disease and 5/6 with obstructive disease underwent PCI (1 after receiving thrombolytics) [
57]. These cases of ST-segment elevation with no obstructive coronary disease on angiography may be related to peri-myocarditis, although the pathophysiology remains under investigation. Importantly, the mortality among patients without no obstructive coronary lesion was higher (90%) than among those with obstructive coronary lesions (50%), although the absolute numbers were limited. A similar incidence of obstructive to non-obstructive coronary lesions was reported in a population of Italian patients with STEMI [
58]. The high prevalence of STEMI mimics in this population further emphasizes the need for angiography (either invasive or non-invasive) as opposed to empiric fibrinolytic therapy given the potential for harm when administering fibrinolytics for non-ACS presentations.
While COVID-19 may potentially increase the risk of ACS, activations for STEMI in the United States have decreased significantly during the pandemic. Among nine high-volume centers in the US, there was a 38% reduction in STEMI activations compared to the 14-month period before the pandemic [
59]. This finding is similar to the 40% reduction in STEMI activations seen in Spain [
60]. It is unclear what is responsible for the significant reduction in STEMI activations, but it may be related to patients’ fear of exposure to SARS-CoV2 when presenting to the hospital. In Hong Kong, China, patients who presented with STEMI during the height of the outbreak presented to the hospital significantly longer after onset of symptoms compared to a year prior (318 vs. 83 min) [
61]. It is currently unknown how many people worldwide may not be seeking medical care for possible ACS due to fear of COVID-19. It is possible that due to delays in seeking appropriate medical care, patients may eventually present to the hospital with heart failure, cardiogenic shock, or mechanical complications from ACS. Studies must be performed to assess the impact COVID-19 could have on cardiovascular mortality through such indirect mechanisms.
SARS-CoV2 infection is theorized to predispose to a hypercoagulable state through inflammation, immune dysregulation, and activation of cytokines. This process has been implicated in ACS, but also in cases of thrombosis outside the coronary arteries. Among 184 ICU patients in the Netherlands, 31% were diagnosed with pulmonary embolism, deep-vein thrombosis, ischemic stroke, myocardial infarction, or systemic embolism—all while receiving standard prophylactic doses of anticoagulation as recommended by the WHO [
62]. Remarkably, none of the patients in this study developed disseminated intravascular coagulopathy (DIC), a known risk factor for the development of arterial and venous thromboembolism in critically ill patients.
D-dimer levels above 1500 ng/ml had a sensitivity of 85% and specificity of 89% for detecting venous thromboembolism in a cohort from China [
63]. Some centers have advocated for the use of treatment dose anticoagulation for select patients with COVID-19 and elevated
D-dimer levels, however this practice has yet to be well validated.
Arrhythmia
Among 187 patients with confirmed SARS-CoV-2 in Wuhan, China, arrhythmia occurred in 5.9% of all patients admitted [
19]. Elevated troponin T was a statistically significant prognostic marker with 82% having either ventricular tachycardia or fibrillation. It is unclear whether elevated troponin preceded or succeeded the arrhythmic events. Furthermore, among 138 patients admitted to a single hospital in Wuhan, China, arrhythmia (type not specified) was reported in 17% with the majority (44%) occurring in critically ill patients in the intensive care unit [
20]. Among patients who suffered a cardiac arrest, the predominant rhythm was asystole/pulseless electrical activity (94%), followed by shockable ventricular tachycardia/fibrillation (6%) [
64]. Similar rates in the New York City population were reported by Goyal et al. Arrhythmia was seen in 7.4% of the entire cohort, with higher rates in the patients receiving ICU care (18.5%) as compared to non-ICU care (1.8%) [
24]. Arrhythmias may be induced by the presence of acidosis and metabolic disturbances, as seen in critical illness with multiorgan dysfunction or catecholaminergic pressor infusion for hypotension and shock. Finally, QT-prolonging agents given to some COVID-19 patients may increase the susceptibility to arrhythmia as discussed below [
65,
66]. Unfortunately, with the limited data available, no trends have been apparent as of yet [
67,
68].
Cardiovascular Considerations with COVID-19 Therapies
There is suspicion that the aggressive nature of the coronavirus pneumonia is related to an exaggerated immune response mediated by interferon and interleukins, as has been seen in prior coronavirus infections [
69,
70]. Targets for COVID-19 therapies are therefore not only focused on the intrinsic viral make up (including proteins such as ACE-2 cell surface receptor, 3-chymotrypsin-like protease, Spike, RNA-dependent RNA polymerase, and papain-like protease) but also the human immune system [
71]. There are currently over 350 active clinical trials searching for treatment options for COVID-19 both in novel therapies as well as repurposed existing therapies, which has the benefit of having a known safety profile. The following table summarizes a selection of these drugs, their mechanisms, known and proposed cardiotoxicities, and ongoing clinical trials (Table
1).
Table 1
Overview of select clinical trials and potential cardiotoxicities [
72‐
85]
Repurposed agents targeting viral entry and replication | Hydroxychloroquine sulfate/chloroquine phosphate ± azithromycin | Dilated cardiomyopathy, QT prolongation | NCT04342221, NCT04307693, NCT04315896, NCT04329923, NCT04345692 |
| Lopinavir/ritonavir | QT prolongation, rhabdomyolysis with statins | NCT04252885, NCT04307693, NCT04307693, NCT04255017 |
| Remdesivir | ?hypotension | NCT04292899, NCT04292730, NCT04323761, NCT04302766, NCT04280705 |
Repurposed agents targeting the immune system | Corticosteroids | Fluid retention, hypertension, electrolyte abnormalities, arrhythmia | NCT04343729, NCT04329650, NCT04327401, NCT04344288, NCT04331054, NCT04348305, NCT04355247 |
| Tocilizumab | Hypertension, hypercholesterolemia | NCT04315480, NCT04320615, NCT04317092, NCT04332913, NCT04306705, NCT04310228, NCT04346355, NCT04332094, NCT04331795 |
| Fingolimod | Hypertension, conduction disease, QT prolongation. Contraindicated in prior MI or known CAD, stroke, conduction disease, prolonged QT, decompensated heart failure | NCT04280588 |
| Convalescent plasma | None reported | NCT04343755, NCT04346446, NCT04342182, NCT04347681, NCT04345523, NCT04344535, NCT04340050, NCT04357106, NCT04327349, NCT04292340, NCT04261426, NCT04264858, NCT04261426 |